Vaccine Technology V
Poster Presentations

1. **Improved rotavirus-like particle production in Saccharomyces cerevisiae by improving the feeding strategy in fed-batch cultures**
   Martha Alicia Contreras, Instituto de Biotecnología UNAM, Mexico

2. **Development of immunogenic virus-like particles as a rabies vaccine candidate**
   Diego Fontana, Universidad Nacional del Litoral, Argentina

3. **Characterization and neutralization studies of a monoclonal antibody against rabies virus glycoprotein**
   Claudio Prieto, Universidad Nacional del Litoral, Argentina

4. **Parameters for MDBK cell growth on microcarriers**
   Ronaldo Mendonça, Instituto Butantan, Brazil

5. **Universal H1n1 influenza vaccine development: identification of consensus class ii hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011**
   Frances Terry, EpiVax, Inc., USA

6. **Synthetic DNA immunoadjuvant IL-33 or CCR10 Chemokine adjuvants drive invivo CD8 T cell and antibody responses that are protective in vivo**
   David Weiner, University of Pennsylvania, USA

7. **Formulation development for a new virosome-based flu vaccine: paving the way towards a temperature resistant liquid product.**
   Francesco Doro, Crucell Hollan BV, Netherlands

8. **Lessons learned for formulation development for live virus vaccines**
   Lynne A. Isopi, Merck & Co, USA

9. **Formulation development and stabilization of a trivalent equine encephalitis virus virus-like particle vaccine candidate**
   Lisa A. Kueltzo, Vaccine Production Program Laboratory, VRC/NIAID/NIH, USA

10. **Nanopatches: For the eradication of poliovirus**
    David Muller, AIBN, University of Queensland, Australia

11. **Development of chemically-defined MDCK and vero culture media for cell-based vaccine development and manufacturing**
    Jenny Bang, Irvine Scientific, USA

12. **Preserving the structural integrity of virus like particles**
    Cuitláhuac Chavez-Peña, Protein Sciences Corporation, USA

13. **Disposable hollow fiber bioreactors for high cell density virus production in continuous mode**
    Yvonne Genzel, Max Planck Institute for Dynamic of Complex Technical Systems, Germany

14. **Case study of influenza H7N9 manufacturing process development in Taiwan**
Alan Yung-Chih Hu, National Health Research Institutes, Taiwan

15. **Manufacturing challenges of adding a preservative containing presentation to a commercial vaccine**
Li Li, Pfizer, USA

16. **High yield expression of leptospirosis vaccine candidate LigA in bioreactor using experimental design**
Marco Medeiros, Oswaldo Cruz Foundation/Bio-Manguinhos, Brazil

17. **Tweaking insect cell platforms for the production of multivalent VLPs: Metabolic profiling, pathway analysis and bioprocess optimization**
Francisca Monteiro, iBET/ITQB-UNL, Portugal

18. **Preparation of pure, high titer, pseudoinfectious flavivirus particles by hollow fiber tangential flow filtration and anion exchange chromatography**
Sophia T. Mundle, Sanofi Pasteur, USA

19. **Evaluation of chromatographic stationary phase for capture of a HIV-1-derived lentiviral vector**
Sara M. Nilsson, University College London, United Kingdom

20. **A tiered methodology to selecting a microcarrier substrate for bioprocess development**
Roberto I. Ortiz, Merck & Co, USA

21. **Enveloped VLPs process development**
Hugo Soares, IBET, Portugal

22. **Development of a phase I/II transient gene expression platform process for production of an enveloped virus-like particle vaccine**
Richard M. Schwartz, Vaccine Production Program Laboratory, VRC/NIAID/NIH, USA

23. **Development of a robust, defined, animal-free virus production medium optimized for microcarrier culture**
Steve Pettit, InVitria, USA

24. **A flow cytometry-based assay for quantification of infectious influenza and vaccinia virions**
Felipe Tapia, Max Planck Institute for Dynamic of Complex Technical Systems, Germany

25. **The comparison of downstream purification process of cell derived influenza vaccine production**
Yu-Fen Tseng, National Health Research Institutes, Taiwan

26. **Assessment of cultivation strategies for the production of Modified Vaccinia Ankara (MVA) at high cell-densities**
Daniel Vázquez, Max Planck Institute for Dynamic of Complex Technical Systems, Germany

27. **In silico prediction of leishmania braziliensis T cell epitope candidates: Towards the development of epitope-based vaccines with protective immunity against cutaneous leishmaniasis**
Vanessa Adaui, Universidad Peruana Cayetano Heredia, Peru

28. **Targeting of rotavirus antigen to skin dendritic cells induces protection against the infection in mice**
Oscar Badillo-Godínez, Universidad Autonoma Del Estado De Morelos, Mexico

29. **Influenza reverse genetics system for use in production platforms of all species**
Bahareh Ramezanpour, Erasmus MC, Netherlands

30. **Manufacture and needle-free intradermal delivery of antibiotic-free NTC RNA-OUT LAMP plasmids**
Aaron E. Carnes, Nature Technology Corporation, USA

31. **Rapid assay for expression and conformational screening of engineered Influenza hemagglutinins for a universal vaccine**
Guadalupe Cortes-Garcia, Sanofi Pasteur, USA

32. **Biological and immunological characterizations of the receptor binding domain of C. difficile toxin A**
Pele Chong, National Health Research Institutes, Taiwan

33. **Improvement of yellow fever virus production in stirred-tank bioreactors using serum-free medium**
Diogo A. Mattos, Bio-Manguinhos/Fiocruz, Brazil

34. **Expression, purification and immunogenicity evaluation of hepatitis A virus recombinant proteins**
Haroldo Cid da Silva Junior, Fundação Oswaldo Cruz / Bio-Manguinhos, Brazil

35. **Continuous influenza vaccine production**
Yvonne Genzel, Max Planck Institute for Dynamic of Complex Technical Systems, Germany

36. **New technologies for detection of viral adventitious agents: challenges and opportunities in vaccine development**
Lucy Gisonni-Lex, Sanofi Pasteur, Canada

37. **Effect of synonymous codon usage bias and co-expression of folding assistant factors on the production of rabies virus glycoprotein in the methylotrophic yeast Pichia pastoris**
Hela Kallel, Institut Pasteur de Tunis, Tunisia

38. **Development of a novel hepatitis E virus vaccine using adeno associated virus : process development and preliminary immunogenicity studies in mice**
Hela Kallel, Institut Pasteur de Tunis, Tunisia

39. **A dose-sparing strategy for pandemic influenza A H7N9 preparedness: One-shot insect cell-derived low-dose H7 virus-like particle preparation protects mice against lethal challenge**
Miriam Klausberger, Vienna Institute of BioTechnology, Austria

40. **Impact of MDCK cell line adaptation to suspension growth on proteome level and virus replication dynamics**
Sabine Kluge, Otto-von-Guericke university, Germany

41. **MVA-based influenza vaccines: bringing these viral vectors from bench to bedside**
Joost Kreijtz, Virosciencelab, Netherlands

42. **Rapid response vaccine technology for the influenza A/H7N9 virus with pandemic potential**
Joost Kreijtz, Virosciencelab, Netherlands

43. **Virus production with the integrity® ICELLIS® single-use bioreactor**
Matthew Kremer, Pall Life Sciences, USA

44. **Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza a vaccine seeds**
Isabelle Legastelois, Sanofi Pasteur, France

45. **Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in leishmania tarentolae**
Isabelle Legastelois, Sanofi Pasteur, France

46. **Novel ETEC vaccine by intranasal immunization**
Yolanda López Vidal, Universidad Nacional Autónoma De México, Mexico

47. **Microbially-produced capsomere: Extending the potential of broadly cross-protecting influenza antigen**
Linda Lua, The University of Queensland, Australia

48. **Monolithic columns for the downstream processing of gene theraphy vectors and vaccines**
Daniela Marc, BIA Separations, Slovenia

49. **Insect cell derived vaccines: Addressing the issue of glycosylation**
Dieter Palmberger, Vienna Institute of BioTechnology, Austria

50. **A viral vector for RNA immunization against rabies. Synthesis, titration and protection studies.**
Carlos Pereira, Instituto Butantan, Brazil

51. **Analysis of the humoral immune response in mice of an inactivated yellow fever 17DD vaccine cultivated in microcarrier-based vero cell cultures**
Diogo Mattos, Bio-Manguinhos/Fiocruz, Brazil

52. **Development of a candidate vaccine for hepatitis C virus**
Hugo Soares, IBET, Portugal

53. **Virus purification via a pseudo-affinity membrane adsorber**
Udo Reichl, Max Planck Institute for Dynamic of Complex Technical Systems, Germany

54. **Vaccine design and evaluation using the iVAX toolkit**
Frances Terry, Brown University School of Public Health, USA

55. **CIMac analytical columns for in-process control of adenoviruses**
Lidija Urbas, BIA Separations, Slovenia

56. **Different immunity elicited by recombinant H5N1 hemagglutinin glycoproteins containing pauci-mannose, high-mannose, or complex type N-glycans**
Suh-Chin Wu, National Tsing Hua University, Taiwan

57. **The two-faced T cell epitope: Judicious antigen selection for optimal vaccine efficacy**
Anne S. De Groot, EpiVax, Inc., USA

58. **One health genome-derived epitope-driven vaccine development for public health and global food security**
Andres H. Gutierrez, University of Rhode Island, USA

59. **Catching a moving target: Universal influenza virus vaccine constructs based on the conserved hemagglutinin stalk domain**
Florian Krammer, Icahn School of Medicine at Mount Sinai, USA

60. **Assessment of the impact of manufacturing changes during the product development on DEC-Her1 physical-chemical and biological characteristics**
Adolfo Castillo Vitlloch, Center of Molecular Immunology, Cuba

61. **CIMAvax-EGF®: Scientific and technological challenges for cancer vaccine manufacturing**
Gryssell Rodriguez, Centro de Inmunologia Molecular, Cuba

62. **Characterization of the Anti-Idiotipic vaccine formulation Racotumumab: Interaction forces with aluminium hydroxide adjuvant and immunogenicity in chikens modifying adsorption and the mAb/adjuvant ratio**
Julio Felipe Santo Tomás, Center of Molecular Immunology, Cuba

63. **Anti-idiotypic monoclonal antibody racotumomab: Impact of glycosylation in biological activity of vaxira vaccine**
Julio F. Santo Tomás, Center of Molecular Immunology, Cuba

64. **Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin-strains with and without aluminium hydroxide adjuvant: clinical trials in adults and infants**
Wilfried A.M. Bakker, Intravacc, Netherlands

65. **Immune history shapes specificity of pandemic h1n1 influenza antibody responses**
Donald M. Carter, Vaccine and Gene Therapy Institute of Florida, USA

66. **Adjuvant manufacturing technology transfer to developing countries**
Christopher B. Fox, IDRI, USA

67. **Pharmaceuticals and security: The role of cross-sectoral collaborations in strengthening global health security**
Anne Roemer-Mahler, University of Sussex, United Kingdom

68. **Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza. implications for vaccine design**
Donald M. Carter, Vaccine and Gene Therapy Institute of Florida, USA

69. **Effect of metal catalyzed oxidation in recombinant viral protein assemblies**
Ricardo M. Castro-Acosta, IBT-UNAM, Mexico

70. **Brazilian meningococcal C conjugate vaccine: Scaling up studies**
Renata Chagas Bastos, Bio-Manguinhos/Fiocruz, Brazil

71. **An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans**
Florian Krammer, Icahn School of Medicine at Mount Sinai, USA

72. **Characterization and quantitative analysis of enterovirus-like particle**
Linda Lua, The University of Queensland, Australia

73. **Development of a universal antibody against multiple strains of influenza virus**
Aziza Manceur, National Research Council, Canada

74. **TEM for characterization of vaccines: Proteins to adjuvants**
Clint Potter, NanoImaging Services, Inc., USA

75.